
Pharma Pulse 10/16/24: Coverage from Access Insights 2024, Racial Inequity in Lung Cancer Screening & more
The latest news for pharma industry insiders.
William Sarraille, professor, University of Maryland Francis King Carey School of Law, discusses breakout session and the impact of healthcare policies on manufacturing and commercialization.
A collaboration between researchers at Massachusetts General Hospital, Boston University, Vanderbilt University Medical Center and the University of Chicago Hospital, explored whether how using a smoking duration cutoff instead of a pack-year one to determine lung cancer screening eligibility would affect the populations eligible for lung cancer screening.
Databricks will tap Amazon’s Trainium chips to power services for building AI systems, a move that could cut costs for businesses.
AllazoHealth, the pioneer in driving therapy initiation, adherence, and health outcomes with artificial intelligence (AI)-powered personalization, today announced that Joy S. Neely, Nagaraja Srivatsan, and Kenneth Ziegler have joined its advisory board. The three executives have extensive backgrounds in life sciences, technology, and enterprise growth strategies, and will provide valuable insights to AllazoHealth as the company initiates plans for product expansions and growth.
"With ubiquitous access to health information about diseases, symptoms, and treatment options through digital channels such as websites, social media and health apps, this patient empowerment is demanding a new level of engagement between patients and healthcare professionals."
This is why having a patient-centric approach to your brand's marketing funnel is important!
Read more insights from Claus Zieler in this Pharmaceutical Executive interview: https://lnkd.in/g28uxynu
#GrowthMarketing #SocialMedia #HealthcareMarketing #PharmaMarketing
Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

